At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
Eleclazine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome
In Brief
A Phase 1 clinical trial evaluating Eleclazine and Placebo for LQT2 Syndrome. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLQT2 Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartJul 2015
Primary CompletionMay 2016
Study CompletionJun 2016
TodayJul 2026
First PostedFeb 19, 2015
Enrollment StartJul 20, 2015
Primary CompletionMay 13, 2016
Study CompletionJun 13, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.4 years ago
Interventions
Eleclazinedrug
Tablets administered orally in a single dose
Placebodrug
Placebo to match tablets administered orally in a single dose